T. Leclercq

发表

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

J. Reynolds, D. White, T. Hughes, 2019, British journal of haematology.

In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy

S. Heatley, D. White, T. Hughes, 2021, Leukemia & lymphoma.

Sphingosine Kinases: Biochemistry, Regulation, and Roles

S. Pitson, M. Pitman, K. Jarman, 2013 .

Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling

M. Vadas, B. Wattenberg, S. Pitson, 2005, The Journal of experimental medicine.

Guanine nucleotides regulate sphingosine kinase 1 activation by eukaryotic elongation factor 1A and provide a mechanism for eEF1A-associated oncogenesis

S. Pitson, P. Moretti, T. Leclercq, 2011, Oncogene.

Cellular signalling by sphingosine kinase and sphingosine 1‐phosphate

S. Pitson, T. Leclercq, 2006, IUBMB life.

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

E. Nievergall, D. White, T. Hughes, 2014, Leukemia.

Low GFI1 expression in white blood cells of CP–CML patients at diagnosis is strongly associated with subsequent blastic transformation

R. D'Andrea, D. White, T. Hughes, 2013, Leukemia.

An oncogenic role for sphingosine kinase 2

D. Creek, S. Pitson, M. Samuel, 2016, Oncotarget.

Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b.

S. Pyne, N. Pyne, R. Bittman, 2012, The international journal of biochemistry & cell biology.

The Sphingosine Kinase 1 Inhibitor 2-(p-Hydroxyanilino)-4-(p-chlorophenyl)thiazole Induces Proteasomal Degradation of Sphingosine Kinase 1 in Mammalian Cells*

V. Natarajan, S. Pyne, N. Pyne, 2010, The Journal of Biological Chemistry.

Eukaryotic Elongation Factor 1A Interacts with Sphingosine Kinase and Directly Enhances Its Catalytic Activity*

M. Vadas, S. Pitson, P. Moretti, 2008, Journal of Biological Chemistry.

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells

D. White, T. Hughes, C. Kok, 2017, Haematologica.

Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy

D. White, T. Hughes, T. Leclercq, 2013, Leukemia & lymphoma.

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia

Damith Ranasinghe, Fred Brown, Haneen Banjar, 2017, PloS one.

A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib

D. White, T. Hughes, C. Kok, 2015 .

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib.

J. Reynolds, D. White, T. Hughes, 2019, Blood advances.

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients

D. White, T. Hughes, C. Kok, 2014, Leukemia.

Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells

D. White, T. Hughes, V. Saunders, 2015, Leukemia.